Skip to main content
. 2018 Aug 14;7(16):e008987. doi: 10.1161/JAHA.118.008987

Figure 3.

Figure 3

Efficacy end points by malignancy status in the higher‐dose edoxaban regimen vs warfarin groups. All efficacy end points are analyzed from the intention‐to‐treat study population. Adj. indicated adjusted; CI, confidence interval; CV, cardiovascular; HR, hazard ratio (adjusted for trial stratification factors); MACE, major adverse cardiovascular event (including myocardial infarction, stroke, or death attributable to CV cause or bleeding); P‐Int, interaction P value; SEE, systemic embolic event.